CGTX · Insider Trading
Cognition Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by CGTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-22 | Ellen B Richstone | Director | A | +25,000 | — |
| 2026-06-22 | Jack A. Khattar | Director | A | +25,000 | — |
| 2026-06-22 | Peggy Wallace | Director | A | +25,000 | — |
| 2026-06-22 | Brett P Monia | Director | A | +25,000 | — |
| 2026-06-22 | BIOS Advisors GP, LLC | Director | A | +250,000 | — |
| 2026-05-04 | John Brendan Doyle | Chief Financial Officer | F | −8,567 | −$10.97K |
| 2026-04-20 | Lisa Ricciardi | CEO & President | Buy | +9,175 | +$10.09K |
| 2026-04-20 | John Brendan Doyle | Chief Financial Officer | Buy | +10,000 | +$11.30K |
| 2026-04-20 | Anthony Caggiano | Chief Medical Officer | Buy | +10,000 | +$11.10K |
| 2026-02-18 | Anthony Caggiano | Chief Medical Officer | F | −4,680 | −$5.24K |
| 2026-02-18 | John Brendan Doyle | Chief Financial Officer | F | −1,560 | −$1.75K |
| 2026-02-18 | Lisa Ricciardi | CEO & President | F | −5,850 | −$6.55K |
| 2026-02-05 | John Brendan Doyle | Chief Financial Officer | MIXED | +173,079 | −$27.73K |
| 2026-02-05 | Anthony Caggiano | Chief Medical Officer | MIXED | +361,593 | −$40.59K |
| 2026-02-05 | Lisa Ricciardi | CEO & President | MIXED | +722,260 | −$82.42K |
| 2025-12-22 | Anthony Caggiano | Chief Medical Officer | MIXED | +44,720 | −$30.42K |
| 2025-12-22 | Lisa Ricciardi | CEO & President | MIXED | +51,600 | −$35.10K |
| 2025-12-22 | John Brendan Doyle | Chief Financial Officer | MIXED | +20,640 | −$14.04K |
| 2025-09-23 | Aaron G.L. Fletcher | Director | M | +7,729 | +$6.49K |
| 2025-07-31 | John Brendan Doyle | Chief Financial Officer | MIXED | +20,640 | −$6.27K |
| 2025-07-31 | Anthony Caggiano | Chief Medical Officer | MIXED | +44,719 | −$13.59K |
| 2025-07-31 | Lisa Ricciardi | CEO & President | MIXED | +51,600 | −$15.68K |
| 2025-06-23 | Brett P Monia | Director | A | +34,000 | — |
| 2025-06-23 | Peggy Wallace | Director | A | +34,000 | — |
| 2025-06-23 | Ellen B Richstone | Director | A | +34,000 | — |
| 2025-06-23 | Jack A. Khattar | Director | A | +34,000 | — |
| 2025-06-20 | Cavu Advisors, LLC | Director | A | +340,000 | — |
| 2025-06-20 | BIOS Fund II QP, LP | Director | A | +340,000 | — |
| 2025-05-02 | John Brendan Doyle | Chief Financial Officer | F | −9,692 | −$4.33K |
| 2025-02-18 | Anthony Caggiano | Chief Medical Officer | F | −5,296 | −$3.13K |
| 2025-02-18 | John Brendan Doyle | Chief Financial Officer | F | −1,723 | −$1.02K |
| 2025-02-18 | Lisa Ricciardi | CEO & President | F | −6,619 | −$3.91K |
| 2025-02-04 | Anthony Caggiano | Chief Medical Officer | MIXED | +282,221 | −$8.51K |
| 2025-02-04 | Lisa Ricciardi | CEO & President | MIXED | +641,191 | +$10.71K |
| 2025-02-04 | John Brendan Doyle | Chief Financial Officer | A | +295,000 | — |
| 2024-06-11 | Peggy Wallace | Director | A | +8,500 | — |
| 2024-06-11 | Brett P Monia | Director | A | +8,500 | — |
| 2024-06-11 | Ellen B Richstone | Director | A | +8,500 | — |
| 2024-06-11 | Jack A. Khattar | Director | A | +8,500 | — |
| 2024-06-11 | Cavu Advisors, LLC | Director | A | +85,000 | — |
| 2024-06-11 | BIOS Capital Management, LP | Director | A | +85,000 | — |
| 2024-05-03 | John Brendan Doyle | Chief Financial Officer | F | −8,699 | −$16.96K |
| 2024-03-14 | Lisa Ricciardi | CEO & President | Buy | +5,700 | +$9.97K |
| 2024-02-20 | Lisa Ricciardi | CEO & President | A | +75,000 | — |
| 2024-02-20 | John Brendan Doyle | Chief Financial Officer | A | +20,000 | — |
| 2024-02-20 | Anthony Caggiano | Chief Medical Officer | A | +60,000 | — |
| 2024-02-09 | Anthony Caggiano | Chief Medical Officer | F | −12,777 | −$29.26K |
| 2024-02-09 | Lisa Ricciardi | CEO & President | F | −27,828 | −$63.73K |
| 2023-11-13 | Cavu Advisors, LLC | Director | A | +5,000,950 | +$5.25M |
| 2023-11-13 | BIOS Memory SPV I, LP | Director | A | +5,000,950 | +$5.25M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Lisa Ricciardi | CEO & President | 1,754,702 | $1.22M |
| Anthony Caggiano | Chief Medical Officer | 874,906 | $607.97K |
| John Brendan Doyle | Chief Financial Officer | 618,942 | $430.10K |
| Aaron G.L. Fletcher | Director | 475,155 | $330.19K |
| Cavu Advisors, LLC | Director | 385,248 | $267.71K |
| BIOS Fund II QP, LP | Director | 358,248 | $248.95K |
| BIOS Advisors GP, LLC | Director | 159,527 | $110.86K |
| Peggy Wallace | Director | 111,461 | $77.45K |
| Ellen B Richstone | Director | 83,500 | $58.02K |
| Brett P Monia | Director | 73,500 | $51.08K |
| Jack A. Khattar | Director | 73,500 | $51.08K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CGTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.